2026-06-14T03:44:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/121762024-11-29T17:05:04Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Martinez-Lage, M author Raul, Torres-Ruiz author Puig-Serra, P author Moreno-Gaona, P author Martin, M C author Moya, F J author Quintana-Bustamante, O author Garcia-Silva, S author Carcaboso, A M author Petazzi, P author Bueno, C author Mora, J author Peinado, H author Segovia, J C author Menendez, P author Rodriguez Perales, Sandra author 2020-10-11 Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9 technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential, we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach presented here might open new horizons for the selective elimination of cancer cells. Nat Commun. 2020;11(1):5060. 10.1038/s41467-020-18875-x 2041-1723 Nature communications 33033246 http://hdl.handle.net/20.500.12105/12176 In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells.